Anti-Hu CD334 Purified

Anti-Hu CD334 Purified
Regulatory status
RUO
Antigen
CD334
Clone
4FR6D3
Format
Purified
Reactivity
Human
Variant
0.1 mg
11-591-C100
In stock
154.00 USD

0.025 mg
11-591-C025
Delivery 1 week
77.00 USD
Variant
0.1 mg
11-591-C100
In stock
154.00 USD

0.025 mg
11-591-C025
Delivery 1 week
77.00 USD
Product details
Description
Images
References
SDS download
Isotype
Mouse IgG1 kappa
Specificity
The mouse monoclonal antibody 4FR6D3 reacts with an extracellular epitope of CD334, the fibroblast growth factor receptor 4, which is an approximately 88 kDa receptor tyrosine kinase expressed in variety of tissues.
Workshop
HCDM listed
Application details
Flow cytometry: Recommended dilution: 2-6 μg/ml.
Reactivity
Human
Immunogen
NIH 3T3 cells transfected with full length human CD334
Concentration
1 mg/ml
Preparation
Purified by protein-A affinity chromatography.
Formulation
Phosphate buffered saline (PBS), pH 7.4, 15 mM sodium azide
Storage and handling
Store at 2-8°C. Do not freeze.
Exbio licence note
The product is intended For Research Use Only. Diagnostic or therapeutic applications are strictly forbidden. Products shall not be used for resale or transfer to third parties either as a stand-alone product or as a manufacture component of another product without written consent of EXBIO Praha, a.s. EXBIO Praha, a.s. will not be held responsible for patent infringement or any other violations of intellectual property rights that may occur with the use of the products. Orders for all products are accepted subject to the Term and Conditions available at www.exbio.cz. EXBIO, EXBIO Logo, and all other trademarks are property of EXBIO Praha, a.s.
Other names
FGFR4, TKF, JTK2, FGFR-4
Antigen description
CD334 / FGFR4 (fibroblast growth factor receptor 4), a transmembrane tyrosine kinase, which is expressed in many tissues, such as in lung, kidney, muscle, heart, pancreas, intestine and other, acts as a receptor for several fibroblast growth factors, namely FGF1, FGF2, FGF6, FGF8, and FGF19. Interaction with these growth factors initiates in cell the signaling cascades leading to the mitogenesis and cell differentiation. Presence of CD334 Gly338Arg allele correlates with prognostic parameters in various cancer studies. CD334 plays multiple roles in the organism, including those of muscle regeneration, cholesterol-to-bile acid metabolism, or glucose homeostasis.
Entrez Gene ID 2264
UniProt ID P22455
11-591 FC
Flow cytometry analysis (surface staining) of CD334 transfectants with anti-CD334 (4FR6D3) purified / GAM-APC.

General references:

Huang X, Yang C, Luo Y, Jin C, Wang F, McKeehan WL: FGFR4 prevents hyperlipidemia and insulin resistance but underlies high-fat diet induced fatty liver. Diabetes. 2007 Oct;56(10):2501-10.
PubMed
Zhao P, Caretti G, Mitchell S, McKeehan WL, Boskey AL, Pachman LM, Sartorelli V, Hoffman EP: Fgfr4 is required for effective muscle regeneration in vivo. Delineation of a MyoD-Tead2-Fgfr4 transcriptional pathway. J Biol Chem. 2006 Jan 6;281(1):429-38.
PubMed
Yang YC, Lu ML, Rao JY, Wallerand H, Cai L, Cao W, Pantuck A, Dalbagni G, Reuter V, Figlin RA, Belldegrun A, Cordon-Cardo C, Zhang ZF: Joint association of polymorphism of the FGFR4 gene and mutation TP53 gene with bladder cancer prognosis. Br J Cancer. 2006 Dec 4;95(11):1455-8.
PubMed
Bange J, Prechtl D, Cheburkin Y, Specht K, Harbeck N, Schmitt M, Knyazeva T, Müller S, Gärtner S, Sures I, Wang H, Imyanitov E, Häring HU, Knayzev P, Iacobelli S, Höfler H, Ullrich A: Cancer progression and tumor cell motility are associated with the FGFR4 Arg(388) allele. Cancer Res. 2002 Feb 1;62(3):840-7.
PubMed
Vainikka S, Partanen J, Bellosta P, Coulier F, Birnbaum D, Basilico C, Jaye M, Alitalo K: Fibroblast growth factor receptor-4 shows novel features in genomic structure, ligand binding and signal transduction. EMBO J. 1992 Dec;11(12):4273-80.
PubMed
Partanen J, Mäkelä TP, Eerola E, Korhonen J, Hirvonen H, Claesson-Welsh L, Alitalo K: FGFR-4, a novel acidic fibroblast growth factor receptor with a distinct expression pattern. EMBO J. 1991 Jun;10(6):1347-54.
PubMed

Product specific references:

Peterson VM, Castro CM, Chung J, Miller NC, Ullal AV, Castano MD, Penson RT, Lee H, Birrer MJ, Weissleder R: Ascites analysis by a microfluidic chip allows tumor-cell profiling. Proc Natl Acad Sci U S A. 2013 Dec 17;110(51):E4978-86.
PubMed
Masuda H, Anwar SS, Bühring HJ, Rao JR, Gargett CE: A novel marker of human endometrial mesenchymal stem-like cells. Cell Transplant. 2012;21(10):2201-14.
PubMed
Variant
0.1 mg
11-591-C100
In stock
154.00 USD

0.025 mg
11-591-C025
Delivery 1 week
77.00 USD
Variant
0.1 mg
11-591-C100
In stock
154.00 USD

0.025 mg
11-591-C025
Delivery 1 week
77.00 USD

Related products

-134%
Reg. statusCE IVD
ApplicationFC
100 ml
220.00 USD
-134%
Reg. statusCE IVD
ApplicationFC
100 ml
66.00 USD
-134%
Reg. statusRUO
ApplicationFC
100 ml
55.00 USD
-134%
CloneMOPC-21
Reg. statusRUO
0.1 mg
115.50 USD